Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China

被引:161
作者
Ming, L
Thorgeirsson, SS
Gail, MH
Lu, PX
Harris, CC
Wang, NJ
Shao, YF
Wu, ZY
Liu, GT
Wang, XH
Sun, ZT [1 ]
机构
[1] Chinese Acad Med Sci, Natl Lab Mol Oncol, Inst Canc, Beijing 100021, Peoples R China
[2] NCI, NIH, Ctr Canc Res, Bethesda, MD 20892 USA
[3] NCI, NIH, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[4] Qidong Liver Canc Inst, Qidong, Peoples R China
关键词
D O I
10.1053/jhep.2002.36366
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We assessed the separate and combined effects of hepatitis B virus (HBV), hepatitis C virus (HCV), and aflatoxin in causing hepatocellular carcinoma (HCC) in Qidong, China. A consecutive series of 181 pathologic-diagnosed HCC cases were studied for hepatitis B surface antigen (HBsAg), anti-HBc, HBV X gene sequence, anti-HCV, the 249ser-p53 mutation, and chronic hepatitis pathology. Each of the 181 incident HCC cases had markers for HBV infection and hepatitis pathology; only 6 of 119 cases were coinfected with HCV. The 249ser-p53 mutation was found in 54% (97/181) of HCC cases and in all 7 cases with tissue for analysis from the hepatitis cohort but in none of 42 matched cases from Beijing. The estimated cumulative dose of aflatoxin B I in these 7 cases ranged from 0.13 to 0.49 mg/kg. Follow-up data through 13.25 years on a cohort of 145 men with chronic HBV hepatitis showed that the relative risk from aflatoxin exposure was 3.5 (1.5-8.1). A similar relative risk was found using 249ser-p53 mutation as a marker for aflatoxin exposure. In conclusion, HBV hepatitis is ubiquitous in Qidong HCC cases, whereas HCV contributes little to its risk. The 249ser-p53 mutation appears to result from coexposure to aflatoxin and HBV infection. Even modest levels of aflatoxin exposure tripled the risk of HCC in HBV-infected men.
引用
收藏
页码:1214 / 1220
页数:7
相关论文
共 39 条
[1]  
ADAMSON RH, 1989, CANCER DETECT PREV, V14, P215
[2]   HEPATITIS-B VIRUS-DNA IN PATIENTS WITH CHRONIC LIVER-DISEASE AND NEGATIVE TESTS FOR HEPATITIS-B SURFACE-ANTIGEN [J].
BRECHOT, C ;
DEGOS, F ;
LUGASSY, C ;
THIERS, V ;
ZAFRANI, S ;
FRANCO, D ;
BISMUTH, H ;
TREPO, C ;
BENHAMOU, JP ;
WANDS, J ;
ISSELBACHER, K ;
TIOLLAIS, P ;
BERTHELOT, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (05) :270-276
[3]  
Breslow NE, 1980, STAT METHODS CANC RE, V1, DOI DOI 10.1097/00002030-199912240-00009
[4]   SELECTIVE G-MUTATION TO T-MUTATION OF P53 GENE IN HEPATOCELLULAR-CARCINOMA FROM SOUTHERN AFRICA [J].
BRESSAC, B ;
KEW, M ;
WANDS, J ;
OZTURK, M .
NATURE, 1991, 350 (6317) :429-431
[5]  
CHEN JG, 1997, IARC SCI PUBL, V143, P322
[6]  
CHEN Z, 1977, CANCER EPIDEM BIOMAR, V6, P523
[7]   Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis [J].
Elmore, LW ;
Hancock, AR ;
Chang, SF ;
Wang, XW ;
Chang, S ;
Callahan, CP ;
Geller, DA ;
Will, H ;
Harris, CC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14707-14712
[8]  
FUJIMOTO Y, 1992, CANCER RES, V52, P1044
[9]  
FUJIMOTO Y, 1994, CANCER RES, V54, P281
[10]   NUCLEOTIDE-SEQUENCE OF THE HEPATITIS-B VIRUS GENOME (SUBTYPE AYW) CLONED IN ESCHERICHIA-COLI [J].
GALIBERT, F ;
MANDART, E ;
FITOUSSI, F ;
TIOLLAIS, P ;
CHARNAY, P .
NATURE, 1979, 281 (5733) :646-650